Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Striverdi

- PMLiVE

Boehringer – Lilly file empagliflozin for European approval

EMA begins review of the companies' new type 2 diabetes drug

- PMLiVE

Boehringer partners with PatientsLikeMe on rare disease community

Collaborates with the online patient community on idiopathic pulmonary fibrosis

- PMLiVE

Boehringer Ingelheim selects Republica as first US agency of record

Cross-cultural marketing agency wins US business for the pharma company's communications strategy

- PMLiVE

GSK’s COPD drug Anoro under review in US

FDA accepts new drug application for the LAMA/LABA combination

- PMLiVE

FDA advisors back Boehringer’s COPD drug olodaterol

Committee votes 15 to 1 in favour despite cancer concerns

- PMLiVE

Boehringer launches COPD patient consultation app for HCPs

Extends reach of the calculator tools on its COPD Exchange website

- PMLiVE

IQWiG knocks back Almirall’s Eklira

Decides added benefit of COPD drug is not proven

- PMLiVE

GSK and Theravance file COPD combo for EU approval

Filing for LAMA/LABA combination comes shortly after US submission

Novartis building

Novartis parts with Eisai to go it alone with COPD drugs

Ends co-promotion agreement for Onbrez, Seebri and QVA149

- PMLiVE

Boehringer and Lilly close in on empagliflozin filing

But amend diabetes alliance after Boehringer drops basal insulin

- PMLiVE

Pharma’s 2012 in … gamification

Boehringer’s headline-grabbing Syrum wasn’t this year's only use of gaming techniques

- PMLiVE

Boehringer talks More Health on new blog

Pharma company's US team looks to connect with 'social entrepreneurs'

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links